Virtual Biotech Companies: Risks Without a Lab 

Can You Build a Pharmaceutical Company Without Owning a Laboratory? 

Starting a pharmaceutical company traditionally involves significant investments in laboratory facilities, research equipment, and scientific personnel. But the industry is changing. 

Today, virtual biotech companies can develop pharmaceutical programs without owning their own laboratories. Instead, they license intellectual property and work with external partners for research, manufacturing, and clinical trials. 

Nimbus Therapeutics is a notable example. The company developed drug discovery programs without maintaining its own traditional wet lab and eventually sold its TYK2 program to Takeda for $4 billion upfront. 

The model creates opportunities for founders to reduce infrastructure costs and focus on scientific development and strategic partnerships. However, outsourcing operations does not eliminate the company’s responsibilities or liability exposures. 

How Does the Virtual Biotech Model Work? 

Rather than managing every stage internally, virtual biotech companies rely on specialized partners. 

Their operations may involve: 

  • Licensing intellectual property: Acquiring rights to university discoveries, compounds, or existing research programs. 
  • Outsourcing research: Using specialist laboratories to conduct experiments and analyze compounds. 
  • Working with CROs: Contract research organizations manage clinical research activities and trial operations. 
  • Outsourcing manufacturing: Contract development and manufacturing organizations produce pharmaceutical materials and products. 

This approach allows smaller companies to access specialized expertise without investing in extensive internal infrastructure. 

Where Do the Liability Risks Begin? 

Working with external partners creates additional responsibilities that pharmaceutical founders need to consider. 

1. Professional and Contractual Liability 

A CRO makes an error in clinical trial data management or fails to meet an agreed research obligation. The pharmaceutical company could face financial losses, contractual disputes, or allegations of professional negligence. 

Professional Liability and Errors and Omissions coverage may be relevant, depending on the services provided and policy wording. 

2. Product and Manufacturing Liability 

A contract manufacturer produces a defective or contaminated batch of pharmaceutical products. Depending on the circumstances, multiple parties could face allegations involving manufacturing quality, product safety, or patient injuries. 

Product Liability and Product Recall coverage address different exposures and should be evaluated separately. 

3. Cybersecurity and Intellectual Property 

Virtual biotech companies depend heavily on digital research platforms, cloud systems, and external vendors. A cyberattack involving a research partner could expose confidential information, clinical data, or valuable intellectual property. 

Cyber Liability coverage and vendor security requirements deserve particular attention. 

4. Clinical Trial Responsibilities 

Outsourcing trial management does not automatically transfer every responsibility to a CRO. Sponsors, investigators, and research organizations must clearly understand their respective obligations, particularly when participant safety and adverse events are involved. 

Clinical Trial Liability coverage may be an important consideration. 

What Insurance Should Virtual Biotech Companies Consider? 

The appropriate insurance program depends on the company’s operations, partnerships, and contractual responsibilities. 

Some potential coverage considerations include: 

Coverage Potential exposure 
Professional Liability / E&O Research and professional service errors 
Product Liability Claims involving defective products or bodily injury 
Clinical Trial Liability Covered claims involving research participants 
Cyber Liability Data breaches and cyber incidents 
Directors and Officers Liability Claims involving management decisions 
Product Recall Eligible product withdrawal and contamination expenses 

Having one policy does not automatically mean every business exposure is covered. Limits, exclusions, contractual requirements, and policy definitions all matter. 

Building a pharmaceutical company without owning a laboratory is becoming a viable business model. Companies can access specialized research, manufacturing, and clinical expertise through strategic partnerships rather than building everything themselves. 

But outsourcing the work does not mean outsourcing every responsibility. 

For biotech founders and pharmaceutical executives, understanding contractual obligations, partner responsibilities, and insurance coverage is essential. 

At Professional Liability Insurance Group, we help businesses evaluate their insurance programs, identify potential coverage gaps, and understand the risks associated with their operations. 

If you’re launching a biotech company or working with external research and manufacturing partners, contact Shayne Bevilacqua to discuss your insurance needs.